Bladder cancer: what’s new in 2019—2020
https://doi.org/10.17650/1726-9776-2020-16-4-147-154
Abstract
This review aims to summarize the latest data on the treatment of bladder cancer published during the specified period. Most of them are evidence-based and were obtained in randomized trials. A new classification based on molecular data was proposed at a consensus meeting of pathologists. A significant correlation has been demonstrated between life expectancy and morphological structure of the tumor. This article covers chemotherapy regimens for patient with BCG (Bacillus Calmette-Guerin) intolerance. Immunotherapeutic agents for muscle-invasive bladder cancer are being actively studied now; scientists are searching for the best treatment regimens with these drugs and their combinations with other antitumor agents. The European Association of Urology has developed a new classification of intraoperative adverse events and recommendations for pharmacotherapy and surgical treatment of patients with bladder cancer during the COVID-19 pandemic. In conclusion, the opinions of experts from the consensus meeting on the treatment of various forms of bladder cancer are given.
About the Author
O. B. Karyakin
A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Competing Interests: not
Russian Federation
4 Koroleva St., Obninsk 249031
Competing Interests: not
References
1. Kamoun A., De Reynies A., Allory Y. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 2020;77(4):420-3. DOI: 10.1016/j.eururo.2019.09.006.
2. Yanagisawa T., Miki J., Sakanaka K. et al. MP73-03 clinical significance of horizontal and vertical margin of EN-BLOC TURBT specimen. J Urol 2020;203:1121-2. DOI: 10.1097/JU.0000000000000959.03.
3. Sathianathen N., Gantz J., Alarid-Escudero F. et al. MP73-07 intravesical chemotherapy for low grade bladder cancer: a cost analysis. J Urol 2020;203:1123-4. DOI: 10.1097/JU.0000000000000959.07.
4. Adele Caruso A., Ravishankar R., VanArsdalen K. et al. MP73-08 intravesical gemcitabine and docetaxol in heavily PRE-TREATED patients with non-muscle invasive bladder cancer (NMIBC). J Urol 2020;203:1123-4. DOI: 10.1097/JU.0000000000000959.08.
5. Herr H. PD51-04 bladder - sparing surgery (BSS) for muscle invasive bladder cfncer (MIBC) after complete response to neoadjuvant chemotherapy (NAC). J Urol 2020;203:1084. DOI: 10.1097/JU.0000000000000953.04.
6. Kool R., Marcq G., Busca J. et al. PD60-01 definitive radiation-based therapy for muscle-invasive bladder cancer: the Canadian multicenter experience. J Urol 2020;203:1273. DOI: 10.1097/JU.0000000000000977.01.
7. Shou J., Cao C., Jiang W. et al. PD51-07 oncologic and functional effectiveness of neoadjuvant chemotherapy followed by surgery plus concurrent chemoradiotherapy or cystectomy for muscle-invasive bladder cancer: preliminary results of a prospective phase II stude. J Urol 2020;203:1085. DOI: 10.1097/JU.0000000000000953.07.
8. Nathan Suskovic N., Raldow A., Royce T. et al. PD55-03 cost-effectiveness of radical cystectomy vs. Trimodality therapy for muscle-invasive bladder cancer. J Urol 2020; 203:1182-3. DOI: 10.1097/JU.0000000000000965.03.
9. European Association of Urology. Guidelines 2020.
10. Elsayed A., Zhe Jing Z., Osei J. et al. PD55-10 outcomes of robot-assisted radical cystectomy in North America vs Europe: results from the international robotic cystectomy consortium. J Urol 2020;203:1186. DOI: 10.1097/JU.0000000000000965.010.
11. Vuky J., Balar A.V., Castellano D. et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 2020;38(23):2658-66. DOI: 10.1200/JCO.19.01213.
12. Grivas P., Plimack E.R., Balar A.V. et al. Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): outcomes in older patients by age and performance status. Eur Urol Oncol 2020;3(3):351. DOI: 10.1016/j.euo.2020.02.009.
13. Necchi A., Raggi D., Bandini M. et al. PD51-01 interim results of PEANUT: an open-label, single-arm, phase 2 study evaluating pembrolizumab plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as salvage therapy for metastatic urothelial carcinoma (UC). J Urol 2020;203:1083. DOI: 10.1097/JU.0000000000000953.01.
14. Biyani C.S., Pecanka J., Roupret M. et al. Intraoperative Adverse Incident Classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel. Eur Urol 2020;77(5):601-10. DOI: 10.1016/j.eururo.2019.11.015.
15. Gillessen S., Powles T. Advice regarding systemic therapy in patients with urological cancers during the COVID-19 pandemic. Eur Urol 2020;77(6):667-8. DOI: 10.1016/j.eururo.2020.03.026.
16. Stensland K.D., Morgan T.M., Moinzadeh A. et al. Considerations in the triage of urologic surgeries during the COVID-19 pandemic. Eur Urol 2020;77(6):663-6. DOI: 10.1016/j.eururo.2020.03.027.
17. Witjes J.A., Babjuk M., Bellmunt J. et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer - an international collaborative multistakeholder effort: under the auspices of the EAU-ESMO Guidelines Committees. Eur Urol 2020;77(2):223-50. DOI: 10.1016/j.eururo.2019.09.035.
Review
For citations:
Karyakin O.B. Bladder cancer: what’s new in 2019—2020. Cancer Urology. 2020;16(4):147-154. (In Russ.) https://doi.org/10.17650/1726-9776-2020-16-4-147-154
Views:
583
Email this article 